Asset profile
ICP-332
Small molecule
Evidence outlook · registrational
Atopic Dermatitis: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2026-11-25.
Also in development:Psoriasis · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
118 competitors in this universe: 3 direct rivals (same mechanism and indication), 1 same-class, 114 same-indication; 36 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| ICP-332: this drug | Phase 3 | Small molecule | TYK2/JAK1 | ||
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | ||
| TLL-018 | Phase 3 | Small molecule | TYK2/JAK1 | ||
| TDM-180935 | Phase 2 | Small molecule | TYK2/JAK1 | ||
| BHV-8000 | Phase 2/3 | Small molecule | TYK2/JAK1 | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | ||
| Brodalumab (Siliq) | Approved | Monoclonal antibody | IL-17 receptor A | ||
| Calcipotriene / Betamethasone Dipropionate Cream (Wynzora) | Approved | Small molecule | Vitamin D receptor + Glucocorticoid receptor | ||
| Calcipotriene / Betamethasone Dipropionate Foam (Enstilar) | Approved | Small molecule | Vitamin D receptor + Glucocorticoid receptor | ||
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | ||
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | ||
| Desoximetasone (Topicort Spray) | Approved | Small molecule | Glucocorticoid receptor agonist |
…and 103 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
2027 (1)
March 2027 (1)
What to watch
2028 (1)
September 2028 (1)
What to watch
2029 (1)
April 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.